Daily or every-other-day plasma exchange for children with Wilson disease
Compares plasma exchange schedules in children with Wilson disease liver failure.
Key facts
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- 10 Nov 2024
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Plasma Exchange
- Standard Medical Treatment
- Record updated
- 21 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with Wilson disease and acute liver failure. It compares plasma exchange every day with plasma exchange every other day.
- Age
- 3 Years to 18 Years
- Sex
- All
- Disease stage
- Wilson disease with acute liver failure, with a New Wilson Index of ≥ 11 and INR ≥ 2.5.
- Biomarker or test result
- New Wilson Index of ≥ 11 and INR (a blood clotting test) ≥ 2.5.
Main reasons for not taking part
- Grade 3 or grade 4 hepatic encephalopathy (severe brain problems caused by liver failure)
- Septic shock (very low blood pressure from a severe infection)
- Disseminated intravascular coagulation (widespread blood clotting problem)
- Very unstable blood pressure needing high doses of vasopressors (norepinephrine >0.5 mcg/kg/min)
- Any severe heart or lung disease from before
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Wilson disease with New Wilson Index of ≥ 11 and INR ≥ 2.5
- Children aged 3 years to 18 years
Who cannot take part
- Any severe cardio-pulmonary pre-existing disease
- Grade 3 or grade 4 hepatic encephalopathy
- Septic shock
- Disseminated intravascular coagulation
- Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine >0.5 mcg/kg/min)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 18 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Wilson disease in children has a varied presentation. Wilson disease with acute liver failure is associated with very high mortality and morbidity. The standard therapy i.e chelation (with either D- penicillamine or trientene can be used as a temporizing agent to treat the enormous release of copper into the blood stream; however, substantial removal is not achieved for at least 1 to 3 months. Plasma exchange provides a means of rapid means of removal of copper. As per American Society for Apheresis, TPE in wilson disease with acute liver failure can rapidly remove an average of 20 mg of copper per TPE treatment. Decreased serum copper may decrease hemolysis, prevent progression of kidney failure and provide clinical stabilization. TPE can also remove large molecular weight toxins (aromatic amino acids, ammonia, endotoxins) and other factors, which may be responsible for hepatic coma. The frequency of said TPE is not defined as most evidence is based on case reports and case series.
Read full original descriptionShow less
Copper is highly protein bound and the volume of distribution for copper is large. Under normal conditions, 90-95% of serum copper is ceruloplasmin-bound with the remaining 5-10% being nonceruloplasmin-bound. TPE efficiently removes both ceruloplasmin- and albumin-bound copper. FFP used for exchange can be helpful in treating the associated coagulopathy. TPE has been used as a bridge to liver transplantation as well as seen to improve survival with native liver, the optimum protocol for same remains uncertain.
The 2 groups in the trial
- Daily plasma exchange + SMTTreatment being tested
(Maximum 3+1 sessions during a period of 7 days)
Treatment: Plasma Exchange and Standard Medical Treatment
- Alternate day therapeutic plasma exchange + SMTExisting treatment, for comparison
Treatment: Plasma Exchange and Standard Medical Treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children: A Randomized Controlled Trial
- Plain-language title
- Daily or every-other-day plasma exchange for children with Wilson diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT06698991, who can take part
- Record updated
- 21 November 2024